July 5, 2017
The Ministry of Health, Labor and Welfare (MHLW) issued a notification on July 4, ordering the addition of sclerosing cholangitis to a list of clinically significant adverse drug reactions (ADRs) in the label of Ono Pharmaceutical’s immuno-oncology drug Opdivo (nivolumab)...read more